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Alzheimer’s disease (AD) is the most common neurodegenerative cause of dementia in
the elderly. AD is accompanied by the accumulation of amyloid peptides in the brain
parenchyma and in the cerebral vessels. The sporadic form of AD accounts for about
95% of all cases. It is characterized by a late onset, typically after the age of 65, with
a complex and still poorly understood aetiology. Several observations point towards a
central role of cerebrovascular dysfunction in the onset of sporadic AD (SAD). According
to the “vascular hypothesis”, AD may be initiated by vascular dysfunctions that precede
and promote the neurodegenerative process. In accordance to this, AD patients show
increased hemorrhagic or ischemic stroke risks. It is now clear that multiple bidirectional
connections exist between AD and cerebrovascular disease, and in this new scenario, the
effect of amyloid peptides on vascular cells and blood platelets appear to be central to AD.
In this review, we analyze the effect of amyloid peptides on vascular function and platelet
activation and its contribution to the cerebrovascular pathology associated with AD and the
progression of this disease.
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ALZHEIMER’S DISEASE AND AMYLOID PEPTIDES
Alzheimer’s disease (AD) is the most invalidating neurological
disorder in the elderly and affects 45 million people worldwide.
In parallel with population aging, AD patients are expected to
rise to 115 million in 2050 worldwide (World Alzheimer Report
et al., 2011).1 The social and economic burden of AD is high and
has been calculated that in the US alone 600 billion dollars per
year are spent for AD patients’ care (The Lancet Neurology et al.,
2010). In the UK, dementia costs the economy more than cancer
and heart disease combined (Alzheimer research UK site). Despite
several promising advances in this field (Blennow et al., 2015),
effective predictive markers of AD are still elusive and diagnosis
relies on cognitive symptoms characteristic of the advanced stages
of the disease. Brain scan and postmortem histological analysis of
brain specimens remain the most reliable tools for AD diagnosis
(Ikonomovic et al., 2008).
AD results in progressive loss of cognitive function
and memory, which ultimately depends on extensive loss
of cerebral tissue functionality linked to neuronal death
(Gandy, 2005). The histological hallmarks of AD throughout
the brain (mainly in the region of hippocampus and
neocortex) are intracellular deposition of hyperphosphorylated
form of the microtubule associated protein tau called
neurofibrillary tangles (NTF) and extracellular accumulation
of amyloid β peptides (Aβ peptides) in senile plaques
1http://www.alz.co.uk/
(Bloom, 2014). Deposits of Aβ peptides are also observed
in the cerebrovasculature, where they may develop cerebral
amyloid angiopathy (CAA; Viswanathan and Greenberg,
2011).
Aβ peptides that accumulate in cerebral senile plaques
and vessel walls derive from the metabolism of the larger
glycoprotein called amyloid precursor protein (APP), which
is a type 1 membrane glycoprotein expressed ubiquitously in
the cells. APP isoform 695 is mainly expressed in neurons,
whereas APP751 and APP770 that contain the Kunitz type
serine protease inhibitory domain KPI are mainly expressed on
peripheral cells and platelets (Van Nostrand et al., 1994). APP
can be processed via two alternative pathways, amyloidogenic and
non-amyloidogenic (Gandy, 2005). The amyloidogenic pathway
produces Aβ peptides by the subsequent action of β- and γ-
secretases. β-secretase proteolyses APP in the extracellular domain
to generate soluble amyloid precursor protein β (sAPPβ) and
a carboxyl terminal fragment named CTFβ (C99), which is the
substrate for γ secretase to produce Aβ peptides. β secretase,
or BACE, is a membrane bound aspartyl protease, for which
APP is a substrate (Vassar et al., 2014). For this reason, BACE
antagonists have been proposed for treatment of AD (Menting
and Claassen, 2014). γ- secretase activity is contained within a
molecular complex formed by the association of four essential
subunits: presenilin1 or presenilin2 (either PS1 or PS2), nicastrin,
presenilin-enhancer-2 (PEN-2) and anterior-pharynx-defective
1 (APH-1; Iwatsubo, 2004). The presenilins are ubiquitously
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expressed and represent the catalytic subunits of γ- secretase,
whereas the other subunits help to stabilize the complex and
to recruit the substrates to be cleaved (Smolarkiewicz et al.,
2013). Alternatively, APP may be proteolysed through the non-
amyloidogenic pathway, via the action of α- and γ-secretase
(Buxbaum et al., 1998). α-secretase cleaves APP within the
Aβ sequence, thus precluding the generation of Aβ peptides.
Cleavage within Aβ sequence of APP by α-secretase generates
soluble amino terminal fragments of 100–130 kDa (sAPPα)
and a carboxyl terminal fragment named CTFα (C83), which
is substrate for γ-secretase (Esch et al., 1990; Vingtdeux and
Marambaud, 2012) to produce the non amyloidogenic peptide p3.
sAPPα generated from the cleavage of APP by α-secretase shows
biological functions in growth regulation and neuroprotection
and, in the case of forms containing the Kunitz-type serine
proteinase inhibitors KPI, in blood coagulation (Xu et al., 2007).
A schematic representation of APP metabolism is presented in
Figure 1.
Aβ peptides are heterogeneous short hydrophobic peptides
(<5 kDa) ranging between 38 and 43 amino acids. Several
different Aβ peptide species exist, but Aβ1–40 (Aβ40) is the
most abundant. Aβ40 peptides contain 16 amino acid residues
in the amino extracellular domain of APP, and 24 amino acids
in the membrane-spanning domain. Aβ42 has two additional
hydrophobic residues, Ile and Ala, and accounts for only
2–5% of Aβ peptides. Aβ42 peptides are more hydrophobic
and fibrillogenic, have a higher aggregation potential and are
the principal species deposited in the brain (Murphy and
LeVine, 2010). Aβ peptides are normally generated in healthy
cells (Seubert et al., 1992), but deficiencies in their clearance
and/or their abnormal production and accumulation in the
brain and in the cerebral blood vessels are correlated with
FIGURE 1 | Amyloidogenic and non-amyloidogenic pathways of APP.
Amyloid precursor protein APP is a single pass transmembrane
glycoprotein. APP may be cleaved by β-γ secretases (amyloidogenic)
releasing amyloid Aβ peptide(s) or by α-γ secretases (non-amyloidogenic).
The two pathways are mutually exclusive and are detailed in the text.
the onset of AD. Aβ peptides in their monomeric forms are
soluble, whereas their oligomerisation leads to the formation
of intermolecular β-sheets and precipitation in senile plaques
(Tjernberg et al., 1999). Aβ oligomers have the ability to
permeabilize the plasma membrane of different cell types,
which triggers a series of cellular event leading to cell
dysfunction and ultimately death. This mechanism of action
is common to different amyloidogenic peptides, including
Aβ peptides, α-synuclein, polyglutamine and APP (Glabe,
2006).
VASCULAR PATHOLOGY IN AD
AMYLOID AND VASCULAR HYPOTHESES
According to the “amyloid cascade hypothesis”, (Hardy and
Higgins, 1992; Hardy and Selkoe, 2002) accumulation of Aβ
peptides in the brain is the central event in the pathogenesis of
AD. Abnormal deposition of Aβ peptides in the brain then cause
plaque and tangle formation, neuronal and vascular damage, cell
loss, and finally dementia. This hypothesis is supported by the
finding that the familial AD (FAD) results from mutations in
genes involved in APP metabolism: APP, PS1 and PS2 (Reznik-
Wolf et al., 1998). These mutations cause abnormal production of
Aβ40 and Aβ42 peptides, which accumulate in the brain and in the
cerebral vessel walls. FAD affects less than 5% of AD cases with
autosomal dominant inheritance. Symptoms develop before the
age of 65 years, and the pathology is particularly aggressive and
leads to death in 5–8 years.
It is noteworthy, however, that the majority of AD patients
(95%) develop the pathology after the age of 65 (Kennedy et al.,
2003). This form of AD is called late onset AD (LOAD) or
sporadic AD (SAD) and has a very complex etiology. The most
common risk factor for LOAD/SAD is aging. A correlation has
been demonstrated for the presence of the ε4 allele for the
cholesterol transporter apolipoproteinE (APOE ε4) and the risk
and the age of onset of AD (Michaelson, 2014). Other risk factors
for LOAD/SAD are hypercholesterolemia, hypertension, Down
syndrome, metabolic syndrome, diabetes, smoking and obesity
(DeFronzo and Ferrannini, 1991; Gorelick, 2004; Morris et al.,
2014).
The etiology of LOAD/SAD remains elusive and the role of
Aβ peptides is controversial (Lee et al., 2004; Sorrentino et al.,
2014). Several lines of evidence point towards a central role
of early vascular dysfunction in the onset of LOAD/SAD. The
“vascular hypothesis” for AD was first proposed in 1993 by
De La Torre, after the observation of extensive abnormalities
of cerebral capillaries in AD brain that finally results in brain
hypoperfusion and reduced cerebral blood flow (de la Torre
and Mussivand, 1993). In this context, it is important to note
that the first case reported by Dr. Alzheimer in 1906 revealed
not only the presence of senile plaques but also the presence
of cerebrovascular dysfunction. In addition, Glenner and Wong
firstly isolated Aβ peptides from the meningeal vessels of a
LOAD/SAD patient in 1984 (Glenner and Wong, 1984). This
led to the coin of the term “vascular dementia”, which indicates
the loss of cognitive functions due to cerebral blood vessel
alteration and poor blood supply to the brain (de la Torre, 2000;
Kara et al., 2012). Vascular dementia and AD are correlated
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and largely overlapping phenomena (Ahtiluoto et al., 2010),
and vascular dysfunctions in the brain are recognized as a
contributing factor to AD (Viswanathan et al., 2009). To date,
many patients with AD present vascular symptoms, including
altered cerebral blood flow, damaged cerebral vasculature, and
abnormal hemostasis (de la Torre, 2004a; Brundel et al., 2012).
Tolppanen et al. demonstrated that AD patients, especially
younger patients, have higher risk of hemorrhagic strokes
(adjusted hazard ratio of 1.34; Tolppanen et al., 2013). Similarly,
a recent Taiwanese population based cohort study showed that
clinical diagnosis of AD is associated with considerably increased
risk of stroke development (odd ratio of 1.66–1.70; Chi et al.,
2013). Moreover, clinical studies indicate that asymptomatic
spontaneous cerebral emboli are highly correlated with AD
(Purandare and Burns, 2009) and that cerebral microinfarctions
occur more likely in AD patients than in healthy controls (Brundel
et al., 2012).
These observations have led to the critical question: “is AD a
neurodegenerative or a vascular disorder?” (de la Torre, 2004b).
Cerebral blood flow is reduced and conversely many vascular
defects are present in patients with AD (Bell and Zlokovic,
2009) and vascular diseases such as atherosclerosis correlate
in severity with dementia and other symptoms of LOAD/SAD
(Farkas and Luiten, 2001; Roher et al., 2003; Casserly and Topol,
2004; Tibolla et al., 2010). Interestingly, vascular risk factors
such as aging, hypercholesterolemia, hypertension, diabetes and
obesity that predispose to atherosclerosis, stroke and cardiac
disease are also associated with cerebrovascular dysfunction,
which might finally results in vascular dementia and the onset of
AD (Morris et al., 2014). Accumulating body of evidence gathered
from human studies and animal models of AD documented
that cerebrovascular dysfunction precedes the development of
cognitive decline and AD pathology (de la Torre, 2010; Jellinger,
2010; Kalaria, 2010). The two-hit hypothesis has been proposed
regarding AD pathogenesis, where vascular dysfunction plays
a primary role in causing neurological injury. Cerebrovascular
abnormalities associated to AD can result in hypoperfusion,
hypoxia, focal chronic inflammation and compromised function
and permeability of brain blood barrier (BBB). These injuries
are exacerbated by Aβ peptides deposition, which may initiate
neurodegeneration and eventually cognitive decline (Zlokovic,
2005; Grammas, 2011; Kelleher and Soiza, 2013; Li et al., 2015).
To date, it has been shown that cerebrovascular dysfunction
accelerates Aβ40–42 production and deposition in the cerebral
vasculature (Honjo et al., 2012) and facilitates the onset of CAA
(Viswanathan and Greenberg, 2011). Aβ peptides are found in
plasma with the levels fluctuating widely among individuals
over time both in AD and in healthy control (the amount of
Aβ40 in healthy subjects varies between 16 to 659 pg/ml, the
amount of Aβ42 from 4 to 149 pg/ml) (Roher et al., 2009). These
data are likely to be affected by the hydrophobic nature of Aβ
peptides, which makes the peptides bind to a variety of plasma
and membrane proteins hindering their effective measurement
in biological fluids. The source of Aβ in plasma is uncertain.
Some authors suggest that plasma Aβ may derive from the
central nervous system through the BBB, but most authors
agree and it is now well recognized that plasma Aβ derives
from endothelial and circulating cells, among them platelets (Li
et al., 1998; Davies et al., 2000). Circulating blood platelets are
the second source of APP protein after the brain and are the
major source of Aβ peptides released in plasma (Li et al., 1998).
Other peripheral sources of Aβ peptides are skeletal muscle (Kuo
et al., 2000; Van Nostrand and Melchor, 2001) and endothelial
vascular cells (Kitazume et al., 2012). Interestingly, Aβ peptides
are able to actively pass the BBB (Deane et al., 2003, 2004), and
the BBB damage typical of cerebrovascular pathologies is likely
to increase the exchange of Aβ peptides between cerebral and
peripheral tissues, including blood. Importantly, a recent study
has demonstrated that peripheral reduction of Aβ peptides is
sufficient to reduce Aβ levels in the brain, which confirms the
extracerebral origin of plasma Aβ peptides (Sutcliffe et al., 2011).
AD AND VASCULAR INFLAMMATION
A number of morphological changes have been observed in the
cerebromicrovascular; these include an overall decrease in intimal
tight junctions (Stewart et al., 1992), basal membrane thickening
(Thal et al., 2003; Kelleher and Soiza, 2013) (particularly found
in areas of Aβ peptides deposition) and intimal atrophy (Farkas
and Luiten, 2001; Truran et al., 2014). In AD brain, substantial
morphological and functional cerebrovascular abnormalities
were observed including, microvasculature irregularities and
atrophy, basement membrane disruption and deposition of
heparin sulfate proteoglycans, collagen IV and laminin, decreased
cerebrovascular network density, endothelial cell alteration i.e.,
increased pinocytosis, decreased levels of mitochondria and
detection of elevated endothelial cell markers VCAM-1 and
E-selectin (Kalaria and Pax, 1995; Farkas and Luiten, 2001;
Bailey et al., 2004; Christov et al., 2008; Zuliani et al., 2008).
These vascular alterations are referred to as CAA, which
associates with ischemic lesions, micro- and macro-hemorrhages,
and impaired cerebral blood flow. Intimal inflammation and
endothelial damage are also likely to contribute to platelet
stimulation in AD patients (Borroni et al., 2002a,b). Vascular
risk factors, frequently present in AD, preactivate endothelial
cells and exacerbate vascular inflammation, which contributes
to CAA (Zhang et al., 2013). The inflammatory proteins
overexpressed in the AD cerebrovasculature are likely to
have toxic effects on neurons, which could represent an
important link between vascular inflammation and neuronal
loss in AD (Tripathy et al., 2013). Failure in the clearance
of Aβ peptides may therefore result in inflammation and
neurotoxicity (Giri et al., 2000; Li et al., 2009) and CAA
is likely to play a key part in brain damage and loss
of cognitive skills typical of AD (Lee et al., 2014). In
accordance to this hypothesis, human studies and animal
models of AD document that cerebrovascular dysfunction
precedes the development of cognitive decline and AD pathology
(de la Torre, 2004b; Bell and Zlokovic, 2009; Xu et al.,
2014).
Several biochemical alterations of endothelial cell physiology
have been identified in response to exposure to amyloidogenic
peptides (Figure 2). Amongst known inflammatory markers,
cyclooxygenase 2 (COX2, a key enzyme for inflammatory
reactions in platelets) expression is increased in mild cognitive
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FIGURE 2 | Cellular and histological effects of amyloid peptide β on
the endothelium. Direct stimulation of the receptor for advanced
glycation end products (RAGE) stimulates NADPH oxidases (NOXs),
intracellular calcium increase and c-Jun N-terminal kinases (JNKs). The
stimulation of NOXs and generation of reactive oxygen species (ROS)
induce the activation of hypoxia-induced factor 1 (HIF) and NF-E2-related
Factor 2 (Nrf2). Together with the activation of JNKs, the activity of
these transcription factors leads to upregulation of pro-inflammatory
genes, including cyclooxygenase 2 (COX2), metalloproteases (MMPs),
interleukins 1β/6/8 (IL1β/6/8), monocyte chemoattractant protein-1
(MCP-1), intercellular adhesion molecule 1 (ICAM-1), tumor necrosis
factor α (TNF α) and transforming growth factor beta (TGF-β). Additional
effect of ROS increase are the reduction of nitric oxide (NO)
bioavailability, which leads to pro-thrombotic endothelial cell phenotype,
and apoptosis. The intracellular calcium increase leads to intimal
loosening via zona occludens protein 1 (ZO-1). The accumulation of
thrombin in the amyloid plaques further facilitates endothelial
inflammation via stimulation of the protease-activated receptors (PARs).
impairment (MCI) and AD patients. This observation links
suggestively well with several studies indicating that treatment
with nonsteroidal anti-inflammatory drugs (NSAIDs) and COX2
inhibitors may reduce the risk of AD (Szekely and Zandi, 2010).
Several studies indicated elevated levels of other inflammatory
mediators in AD cerebral microcirculation, where endothelial
cells overexpress adhesion molecules (MCP-1, ICAM-1, CAP37),
and inflammatory and stress markers such as TNFα, TGF-β,
interleukins (IL-1β, IL-6, IL-8) and matrix metalloproteases
(MMPs; Grammas and Ovase, 2001; Grammas et al., 2002;
Thirumangalakudi et al., 2006; Yin et al., 2010; Grammas,
2011). In vitro studies on cultured endothelial cells revealed
that exposure to Aβ40 increased the levels of inflammatory
cytokines, including IL-6, IL-1β, MCP-1, and GRO because
of JNK-AP1 activation (Vukic et al., 2009). AD senile plaques
also display elevated levels of thrombin (Akiyama et al., 1992).
Besides its central role in hemostasis, thrombin is a factor
with complex paracrine activity that mediates a wide array of
cellular processes involving inflammation, neurotoxicity and
angiogenesis. Thrombin release activates endothelial cells and
enhances their expression of proinflammatory proteins such as
ICAM-1 and MCP-1, angiopoietin-2 release, and up-regulation
of αVβ3 integrin of VEGFRs expressions (Grammas and Ovase,
2001; Tsopanoglou et al., 2002). Observations obtained from
in vivo and in vitro studies, showed that thrombin can cause
accelerated tau protein aggregation, neuronecrosis and can incite
neurotoxic effects through multiple mechanisms (Smirnova et al.,
1998; Suo et al., 2003; Mhatre et al., 2004; Park and Jin, 2008; Rao
et al., 2009).
AD AND REDOX BALANCE IN VASCULAR CELLS
Another significant change in endothelial cells associated with
AD is the overexpression of receptor for advanced glycation end
products (RAGE). RAGE facilitates soluble Aβ peptides transport
across BBB and across the cortical neurons intracellular space
(Yan et al., 1996; Sasaki et al., 2001; Takuma et al., 2009).
These findings suggest a role of RAGE in Aβ deposition in
the cerebral intracellular space and thereby in the enhancement
of AD-associated neuronal damage (Lue et al., 2001; Takuma
et al., 2009). Moreover, Aβ interaction with RAGE at the BBB
contributes to the up-regulation of endothelial CCR5 expression,
in a dose- and time-dependent manner, via activating Egr-
1 transcription factor through JNK, ERK and PI3K pathways
(Li et al., 2009). The upregulation of CCR5 stimulates trans-
endothelial migration of circulating T cells that express high
levels of CXCR2 and MIP-1α. MIP-1α induces the opening
of endothelial tight junctions (Li et al., 2009). It has been
shown that increased RAGE expression facilitates the generation
of reactive oxygen species (ROS) via NADPH oxidase (NOX)
in cerebral endothelial cells and up regulates adhesion and
pro-inflammatory molecules (Askarova et al., 2011). ROS are
highly reactive molecules that promotes cell damage by direct
modification of nucleic acids and proteins. One immediate
consequence of increased ROS generation in cerebrovascular
cells is the reduction of NO bioavailability through its
transformation in the physiological oxidant peroxynitrite (NO3;
Beckman and Koppenol, 1996). Aβ also exerts an inhibitory
effect on NO signaling via binding to cell surface receptors
CD36 and CD47 and inhibiting sGC/cGMP/cGK signaling
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pathways; thus contributing to the lack of NO signaling
observed in AD (Miller et al., 2010). Because of the important
antiplatelet and vasorelaxant activity of NO, its reduction
in the presence of increased ROS in AD brain is likely to
promote platelet activation and thromboembolic consequences.
Several in vitro studies on Aβ peptides showed decreased NO
production in endothelial cells in a dose dependent manner
at Aβ concentrations of (10−9−10−6 M) and cerebrovascular
endothelium desensitization to acetylcholine, which is an
endothelium dependent vasodilator, at Aβ concentration of
10−8 M (Grammas et al., 1995; Price et al., 2001; Hayashi et al.,
2009).
In addition, ROS can activate redox-sensitive transcription
factors hypoxia-inducible factor 1α (HIF1 α) and nuclear factor
(erythroid-derived 2)-related factor 2 (Nrf2), which modifies
gene expression of endothelial cells and can ultimately lead
to the up-regulation of apoptotic/inflammatory genes (Wautier
et al., 2001; Fonseca et al., 2014). Accumulative body of evidence
recently shows that the main culprit behind cerebrovascular
dysfunction in AD is oxidative stress and ROS production mainly
by NOX induced by Aβ that eventually triggers apoptosis in
association with neurovascular inflammation (Cai et al., 2003;
Park et al., 2005). High levels of pro-angiogenic gene expression
have also been documented in AD brains using genome-wide
expression profiling and includes the expression of vascular
endothelial growth factor (VEGF), HIF-1α, angiopoietin-2 and
thrombin (Pogue and Lukiw, 2004; Thirumangalakudi et al.,
2006). This is likely to be an adaptive yet inefficient response to
poor blood flow and ischemia in AD brains. In fact, AD cerebral
tissue is characterized by reduced cerebromicrovascular density
(Brown and Thore, 2011). Despite the increased expression
of factors that promotes angiogenesis and neovascularization,
several studies demonstrated an overall decrease in vasculature
density in AD brains. It has been suggested that vascular-restricted
mesenchyme homeobox 2 gene (MEOX2) signaling is impaired
in AD patients, which interferes with the process of angiogenesis
(Jellinger, 2002; Paris et al., 2004; Wu et al., 2005).
AD AND Ca2+ HOMEOSTASIS IN VASCULAR CELLS
In addition to ROS, different cell populations in AD patients
and animal models of the disease documented deregulation
of Ca2+ homeostasis (Berridge, 2013; Garwood et al., 2013).
Aβ has been shown to form cation permeable pores in the
plasma membranes (Pollard et al., 1993) and it has been
demonstrated that Aβ toxicity derives from the deregulation of
Ca2+ homeostasis (Demuro et al., 2005). Mitochondrial Ca2+
overload causes mitochondrial depolarization and impairs the
electron transport chain, which increases ROS generation in
vascular cells (Carvalho et al., 2009). Ca2+ overload can directly
activate NOXs (De Bock et al., 2013) and contribute to the
redox stress of AD cerebral tissue. Ca2+ modulation seems to
be critical for the onset of redox stress in endothelial cells. Aβ40
induces mitochondria-mediated apoptotic endothelial cell death
pathway involving ER-to-mitochondria Ca2+ transfer, decrease
of mitochondrial membrane potential, and release of pro-
apoptotic factors (Fonseca et al., 2013). Recent studies showed
that short-term treatment with a toxic dose of Aβ40 inhibits
Ca2+ retention in the endoplasmic reticulum and enhances
adenosine triphosphate (ATP)-stimulated release of intracellular
Ca2+ (Fonseca et al., 2014). Importantly, Aβ-RAGE interactions
in cultured endothelial cells increase intracellular Ca2+ and alter
tight junction proteins through the Ca2+-calcineurin pathway
(Kook et al., 2012). This phenomenon is responsible for the
reduction of zonula occludin-1 (ZO-1) expression and increased
MMP secretion observed in cultured endothelial cells and can
ultimately be the cause of enhanced MMP secretion and loss of
vascular integrity in the vicinity of Aβ plaques in animal models of
AD (Kook et al., 2012). The resulting Aβ-dependent alteration in
the integrity of the BBB may play a significant role in the transport
and accumulation of Aβ peptides from the circulation to the brain
parenchyma.
PLATELET PATHOLOGY IN AD
APP AND Aβ PEPTIDES IN PLATELETS
The bidirectional correlations between AD and vascular diseases
points to an important role for non-neuronal cells and
extraneuronal generation of Aβ peptides in the development of
AD. Circulating platelets, which are anucleate cells responsible
for hemostasis and thrombosis, are good candidates for the
link between vascular diseases and AD. Platelets express mainly
the APP isoforms 751 and 770. These isoforms contain the
56 amino acids long Kunitz type serine protease inhibitors
domain KPI, which is known to inhibit serine proteases including
those of the coagulation cascade (Van Nostrand et al., 1989;
Xu et al., 2005, 2007). In addition, platelets express all the
enzymatic machinery responsible for APP metabolism and for
the generation of Aβ peptides (Evin et al., 2003; Catricalà
et al., 2012). In physiological conditions, platelets metabolize
APP through the non-amyloidogenic pathway: α-secretase is
activated by Ca2+ and calmodulin (Canobbio et al., 2011) and
releases soluble APPα. To a lesser extend platelets also release
Aβ peptides. The main species of Aβ released from activated
human platelets is Aβ40, while the predominant form in neuronal
plaques is Aβ42. Immunoassay analysis has revealed that the
inactivated platelets had an average of 84 ng/g tissue of Aβ40
and activated platelets contained an average of 57 ng/g tissue,
while in both cases there were very low levels of Aβ42: 1.6 ng/g
tissue and 1.7 ng/g tissue, respectively (Kokjohn et al., 2011). APP
fragments and Aβ peptides are stored in platelet α-granules as
revealed by immune electron microscopy (Li et al., 1994) and
sucrose density gradient (Van Nostrand et al., 1990), and are
released upon stimulation with physiological agonists (Li et al.,
1994). Increasing evidence suggests that released Aβ peptides
are able to activate platelets and promote platelet adhesion
and aggregation (Shen et al., 2008a,b; Canobbio et al., 2013,
2014). This eventually results in enhanced thrombus formation
in vitro and in vivo (Gowert et al., 2014; Sonkar et al., 2014).
On the contrary, soluble APP fragments have been shown to
regulate thrombosis and hemostasis in vivo (Xu et al., 2005,
2007).
The relatively abundant concentration of APP in platelets
(9300 copies/platelet) (Rowley et al., 2011) and the predominant
presence in platelets of the KPI containing isoforms suggest
that APP may have a physiological role, mainly in events
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associated with coagulation (Van Nostrand et al., 1992; Xu
et al., 2005). A minority (10%) of APP is expressed as an
intact glycoprotein on the platelet surface where it may act as
a receptor on the platelet surface (Kang et al., 1987; Li et al.,
1994). Fibrillar Aβ but not unassembled Aβ, specifically binds
to APP (Lorenzo et al., 2000; Van Nostrand et al., 2002; Sola
Vigo et al., 2009). APP also can bind to sulfated proteoglycans,
laminin, collagen and integrin like receptor, suggesting a role
in cell-cell and cell- matrix interactions (Breen et al., 1991;
Ghiso et al., 1992; Milward et al., 1992; Beher et al., 1996;
Williamson et al., 1996; Verdier and Penke, 2004). Moreover
several studies have reported that treatment of neuronal cell
with monoclonal antibody 22C11 directed toward the N terminal
domain of APP can stimulate G protein activity (Okamoto
et al., 1995) and/or cause the dimerization of APP (Scheuermann
et al., 2001). Notably, APP metabolism resembles that of Notch
(Nakayama et al., 2011): in the canonical Notch signaling
pathway, γ-secretase cleaves Notch in the plasma membrane
and release an intracellular domain that shows activity in the
nucleus through binding to transcription factors. Since platelets
are anucleate cellular fragments this consideration deserve further
investigation.
APP is proteolytically cleaved during platelet activation (Li
et al., 1998; Evin et al., 2003). The released soluble APP
fragment that contain KPI domain was firstly identify as Protease
Nexin 2 PN-2, a chymotrypsin inhibitor and regulator of blood
coagulation (Van Nostrand et al., 1989). More recently it has been
shown by the same authors that PN-2 coincide with soluble APP
fragment containing KPI (Van Nostrand et al., 1992). Soluble APP
inhibits the activity of the blood coagulation factors IXa, XIa, and
Xa, and, to a lesser extent, of factor VIIa-tissues factor complex
(Smith et al., 1990; Van Nostrand et al., 1992; Schmaier et al.,
1995; Scandura et al., 1997) and may therefore play a role in
the coagulation cascade, thus modulating hemostasis following
vascular injury by limiting thrombosis. Xu et al. generated specific
transgenic mice which expressed human APP770 in platelets,
under the control of rPF4 promoter. Transgenic mice express
2 fold higher APP770 amount in platelets, but not in other
analyzed tissues. They investigated the APP function comparing
Tg-rPF4/APP mice with wild type mice and with mice which do
not express APP at all (APP KO) and demonstrated that KPI-
containing forms of APP regulates cerebral thrombosis in vivo
in a carotid artery thrombosis and in experimental intracerebral
hemorrhage (Xu et al., 2005, 2007). In accordance to this,
recombinant soluble APP has been shown to inhibit platelet
aggregation and secretion induced by ADP and adrenaline in vitro
(Henry et al., 1998).
Aβ PEPTIDE-DEPENDENT ACTIVATION OF PLATELETS
It has been widely demonstrated by several authors that Aβ
peptides are able to activate platelets (Figure 3). The first study
date back to 2007 and analyzed the effects of misfolded proteins
on platelet activation. Herzenik et al. showed that proteins with
amyloid properties, including Aβ peptides, activate platelets.
Fibrillar Aβ peptide induces platelet aggregation through
the scavenger receptor CD36 and GPIbα, and activation
of intracellular signaling pathways involving p38MAPK,
cyclooxygenase1 (COX1) and thromboxane A2 production
(Herczenik et al., 2007). More recently, the ability of amyloid
peptides to activate platelets has been investigated using the
synthetic peptide Aβ25–35. This undecapeptide is located in the
intermembrane domain of APP and retains the toxic properties of
the entire peptide representing the biologically active region of Aβ
(Kang et al., 1987). Aβ25–35 toxicity resides in the ability to form
oxygen radicals, nitric oxide and to disrupt calcium homeostasis
(Kaminsky et al., 2010). In preliminary studies, Aβ40 and Aβ25–35
showed equal potencies in inducing platelet activation (Shen
et al., 2008a). Exogenous Aβ25–35 (1–2 µM) potentiated agonist-
induced platelet aggregation induced by collagen and ADP, and at
higher concentrations (2–10µM) Aβ25–35 itself directly promotes
aggregation, and activation of intracellular signaling pathways
through thrombin receptor PAR1 activation of p38 MAPK and
cytosolic PLA2, and TxA2 formation (Shen et al., 2008a). In
addition, the same authors demonstrated that Aβ25–35 stimulates
PLC/PKC activation and Ca2+ mobilization (Shen et al., 2008b).
Aβ25–35 also induced the activation of small GTPase RhoA and
phosphorylation of myosin light chain kinase, which leads to
cytoskeletal reorganization and results in shape change, granule
release, integrin activation and clot retraction. An essential
role for Ca2+ and ADP in Aβ -induced platelet activation and
thrombus formation has been recently demonstrated by our
group (Canobbio et al., 2014). We have demonstrated that the
first event in Aβ-induced platelet activation is the increase of
intracellular Ca2+ concentration. Our results confirmed and
extended previous observations by Galeazzi et al., on Aβ25–35-
induced intraplatelet Ca2+ mobilization (Galeazzi et al., 2000).
Aβ-induced intracellular Ca2+ movements rely on the presence
of extracellular Ca2+, this result is in line with the evidence
that Aβ is able to form cation permeable pores in the plasma
membranes (Pollard et al., 1993) and that Aβ toxicity derives
from the deregulation of Ca2+ homeostasis (Demuro et al., 2005).
Intracellular Ca2+ increase in platelets promotes acto-myosin
cytoskeletal reorganization, granule secretion and ADP release.
Once released ADP is able to reinforce and promote platelet
activation in term of phosphorylation of selected signaling
proteins, mainly the non receptor tyrosine kinase Syk, PI3K,
PKC and MLC, activation of the small GTPase Rap1b, inside-out
activation of integrin αIIbβ3, and finally aggregation (Canobbio
et al., 2014).
We have demonstrated that platelets are also able to adhere
and spread over immobilized Aβ25–35 as well as Aβ40 and Aβ42,
to accelerate platelet adhesion over collagen (Canobbio et al.,
2013; Gowert et al., 2014), and to increase platelet spreading over
fibrinogen (Sonkar et al., 2014). Interestingly, platelets adhere
to Aβ peptides independently of ADP but are able to activate
several intracellular signaling pathways associated with platelet
stimulation dependently on the release of ADP. Aβ peptides also
enhance adhesion to collagen under shear (Canobbio et al., 2014)
and potentiates thrombus formation in vivo, as revealed in a
mouse model of pulmonary thromboembolism (Sonkar et al.,
2014). The effect of Aβ in promoting platelet activation in vivo was
confirmed in injured carotid artery model (Gowert et al., 2014).
More interestingly, the effect of amyloid peptides was analyzed
in APP transgenic mice. APP23 and APP Dutch mice are known
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FIGURE 3 | Aβ peptides-induced platelet activation. Aβ peptides present in
plasma activate platelets inducing activation of PLC/PKC and intracellular
Ca2+ movement, granule secretion, kinase activation, rap1b mediated-integrin
activation and aggregation. Aβ peptides released from α-granules, ADP
released by dense granules, and formation of TxA2 reinforce platelet
activation. Aβ peptides also promotes ROS formation, caspase activation and
membrane scrambling. Activated platelets recruit leukocytes and promotes
vascular inflammation.
to develop CAA upon aging and to deposit amyloid peptides in
the cerebral vessel walls. Gowert et al. analyzed brain of these
transgenic mice for Aβ deposition and platelet recruitment and
demonstrated that platelets adhere to vascular amyloid plaques
with time and that sustained platelet recruitment may lead to full
occlusion of the vessel (Gowert et al., 2014).
Aβ peptides regulate phosphatidylserine exposure, micro
-particles production and caspase activation, suggesting a
transition of platelets from activation to apoptosis (Gowert et al.,
2014). Recently, it has been demonstrated that mitochondrial
respiration is increased in Aβ-stimulated platelets (Sonkar et al.,
2014). In addition, ROS generation in platelets is significantly
increased by exposure to Aβ peptides (Gowert et al., 2014).
Moreover, cytochrome c oxidase, an enzyme that belongs to the
complex IV of the respiratory chain, has been observed to be
diminished in platelets and hippocampal mitochondria of AD
patients (Bosetti et al., 2002). This result was confirmed by other
studies, and is correlated with increased ROS formation in AD
platelets (Cardoso et al., 2004). Taken together, these studies
point toward an increased oxidative stress in AD patients. There
is therefore the possibility that Aβ peptides stimulate/increase
platelet activation by inducing a state of redox stress, which has
been shown to increase platelet responsiveness. For example,
O2—has been suggested to stimulate platelet hyperactivity
in anoxia/reoxygenation conditions (Leo et al., 1997) and
hypercholesterolemia (Stokes et al., 2007). The dependence of
platelet activation on ROS generation explains the inhibition
of platelets and the anti-thrombotic effect of antioxidants
(Freedman, 2008) or ROS-generating enzyme inhibitors (Vara
et al., 2013).
Table 1 summarize the effects of Aβ peptides on platelet
activation.
ANIMAL MODELS OF AD AND PLATELET AND VASCULAR
(DYS)FUNCTIONS
Since the formulation of the “amyloid cascade hypothesis”
and the discovery of mutations correlated with FAD, several
AD transgenic mice have been developed to study the
pathophysiological role of APP and Aβ peptides. In most cases,
AD transgenic mice express mutant human APP or PS1/PS2
genes (one single or more mutations correlated with AD onset
in FAD). In addition, mice that do not express APP have been
generated to investigate the physiological role of APP in cellular
signaling. The number of murine model for AD is exponentially
growing and for an extensive list of AD model mice we suggest
to refer to http://www.alzforum.org/research-models. These mice
have been extensively studied as a model for the onset of AD,
and to investigate the mechanism underlying amyloid deposition
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Table 1 | Principal molecular effects of amyloid peptides on platelets.
Amyloid peptide Molecular effects on platelets References
Aβ1–40 promotes platelet aggregation Herczenik et al. (2007)
promotes ROS formation, caspase activation, annexin V exposition
and membrane scrambling
Gowert et al. (2014)
promotes platelet adhesion under static and dynamic flow conditions Canobbio et al. (2013), Gowert et al. (2014)
increases platelet adhesion in an injured carotid artery model Gowert et al. (2014)
modulates soluble Aβ into fibrillar Aβ Gowert et al. (2014)
recruits platelets to vascular amyloid plaques Gowert et al. (2014)
Aβ25–35 induces platelet adhesion in static conditions Canobbio et al. (2013)
fastens platelet spreading over collagen Canobbio et al. (2013)
increases platelet spreading over fibrinogen Sonkar et al. (2014)
increases adhesion to collagen under shear Canobbio et al. (2014), Sonkar et al. (2014)
promotes platelet aggregation Shen et al. (2008b), Canobbio et al. (2014),
Sonkar et al. (2014)
potentiates platelet aggregation induced by
collagen and ADP
Shen et al. (2008a)
promotes Ca2+ mobilization and granule secretion Galeazzi et al. (2000), Canobbio et al. (2014),
Sonkar et al. (2014),
activates PLC and PKC Shen et al. (2008b)
activates Syk, PI3K/Akt, MAP kinases Canobbio et al. (2013, 2014)
induces RhoA and Rap1b activation Canobbio et al. (2014), Sonkar et al. (2014)
induces Rap1b and integrin activation Canobbio et al. (2014), Sonkar et al. (2014)
triggers hydroxyl radical formation Shen et al. (2008b)
induces clot retraction Sonkar et al. (2014)
shortens platelet plug formation in mesenteric venules in mice Shen et al. (2008b)
induces thrombus formation in a model of pulmonary thromboembolism Sonkar et al. (2014)
in brain parenchyma and cerebral vessels, their correlation with
cognitive impairment, and to develop new therapeutic strategy.
However, only few of these murine models have been utilized for
analysis of possible peripheral platelet and vascular dysfunctions.
The prothrombotic phenotype observed in AD patients and
related to pre-activated platelets has been demonstrated in AD
transgenic mouse models. Recently, Jarre et al. analyze platelet
activation in APP23 mice which carry human APP751 containing
the Swedish (KM670/671NL) under the neuronal Thy promoter.
These mice deposit Aβ peptides in the brain parenchyma and in
the cerebral vessel walls developing CAA upon aging. In this study
the authors have demonstrated that platelets of aged Alzheimer
transgenic mice APP23 are in a pre-activated state and respond
with enhance platelet activation upon stimulation. This finally
results in a pro-thrombotic phenotype with altered hemostasis
and increased thrombus formation in vivo (Jarre et al., 2014).
Not only platelets, but also cerebrovasculature is activated in
AD transgenic mice. Grammas et al. analyzed two transgenic
AD animal models: AD2576APPSwe and La Ferla3xTG which
overexpressed Aβ in the brain and demonstrated that brain
endothelial cells overexpressed Aβ, thrombin, tumor necrosis
factor α, interleukin-1β and interleukin 6 and MMP9 (Grammas
et al., 2014). Inflamed endothelial cells also release APP770
(Kitazume et al., 2012). Aβ and thrombin expressed from
endothelial cells in turn strengthen platelet activation thus
reinforcing chronic inflammation and thrombus formation.
ANTI PLATELET THERAPIES AND AD
Aβ peptides released by platelets and endothelial cells result in
platelet activation and vascular inflammation with dangerous
consequences for the progression of AD. With this background,
it seems reasonable that the use of antiplatelet agents and/or
NSAIDs may slow down AD. We have previously reported in
this review that treatment with COX2 inhibitors may reduce the
risk of AD (Szekely and Zandi, 2010). Epidemiological studies in
the past have suggested that patients taking NSAIDs or aspirin
display some level of protection from AD (Henderson et al.,
1997; Aisen et al., 2000; Broe et al., 2000; in ’t Veld et al., 2002;
Thal et al., 2005; ADAPT Research Group et al., 2007). Aspirin
is the most common anticoagulant used in prevention of stroke
and myocardial infarction (Yeung and Holinstat, 2012; Zhang
et al., 2013). Aspirin is an irreversible inhibitor of cyclooxygenase
1 that catalyzes the synthesis of an important platelet agonist
thromboxane A2 (Loll et al., 1995). At high doses (5 g per day)
aspirin inhibits prostaglandin production by white blood cells and
has therefore anti-inflammatory action, whereas at low doses (75
mg) per day has mainly anti platelet activity. Aspirin is commonly
used in the treatment of vascular dementia (Molnar et al., 1998).
The AD 2000 collaborative group analyzed for 3 years the effect
of low dose aspirin daily administration on 156 AD patients
compared to 154 AD patients who did not take aspirin. The
outcomes evaluated were cognition and functional ability. The
results showed no benefits of aspirin on the progression of AD
in the analyzed subjects. On the contrary, 8% of patients taking
aspirin had serious bleed and 2% of patients in the aspirin group
had fatal cerebral bleed (AD2000 Collaborative Group et al.,
2008). These results advice against the use of aspirin in AD, since
the risks overweigh any benefits. However, more studies on aspirin
or other antithrombotic drugs are necessary to understand the
potential of these drugs in the treatment of AD. It is conceivable
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that the administration of antithrombotic or anti-inflammatory
drugs is not effective on AD when the pathology is overt, but may
be important in prevention of the disease in individuals at risk.
PLATELET ABNORMALITIES IN AD
Many alterations have been observed in platelets from AD patients
compared to age matched control subjects, but attention must be
taken when considering the data found in the literature. The most
important and reliable changes observed in platelets from AD
patients are reduced APP ratio, alteration of α- and β-secretase
expression or activity that result in abnormal APP metabolism
through the amyloidogenic pathway, and enhanced platelet
activation. In addition, changes in expression and/or activity of
Monoamine oxidase B (MAO-B), cytochrome c oxidase, and
cicloxygenase2 have been reported in platelets isolated from
AD patients. For a comprehensive and exhaustive analysis of
alterations in platelets from AD patients refer to the recent paper
by Veitinger et al. (2014).
Altered APP ratio
APP is present on plasma membrane as an intact glycoprotein of
about 110/130 kDa and as soluble fragments of different length
in platelet α-granules. Based on the electrophoretic mobility of
anti-APP antibody 22C11-immunoreactive bands it is possible
to reveal at least two isoforms of APP in platelets: a higher
band at 130 kDa and a lower band at about 106/110 kDa. The
difference in electrophoretic mobility between the 130 kDa and
the 106–110 kDa bands has been attributed to the presence
or absence of KPI, respectively. The APP upper to lower band
ratio is lower in platelets from patients affected by MCI and
SAD compared to platelet prepared from control subjects and
patients affected by other kind of dementia (Di Luca et al., 2000;
Borroni et al., 2005, 2010). The altered APP ratio in platelets
shows a positive and specific correlation to the progression of the
disease. This correlation is also present in preclinical stages of AD,
suggesting that this can be as a useful biomarker for AD.
Altered secretase activation and APP metabolism
Platelets metabolize APP preferentially through non-
amyloidogenic α-secretase pathway. In platelets from AD
patients, the expression of α-secretase candidate ADAM10 is
decreased compared to healthy subjects (Colciaghi et al., 2002;
Tang et al., 2006). On the other hand, an increased β-secretase
activity has been indirectly shown by a decreased ratio of its
37/56 kDa fragments (Colciaghi et al., 2004; Tang et al., 2006).
The increased β-secretase activity was also demonstrated directly
by enzymatic assay in the early stage of AD and MCI patients
compared to control (Liu et al., 2007; Johnston et al., 2008), and
by increased level of β-secretase product sAPPβ (Colciaghi et al.,
2004). Taken together, this switch from non-amyloidogenic to
amyloidogenic in the APP pathway is likely to be responsible for
the increase in platelet-derived Aβ peptides generation.
Monoamine oxidase-B activity
MAO-B is responsible for the degradation of neurotransmitters
in the nervous system (e.g., dopamine) and expressed in platelets
(Paasonen et al., 1964). Several studies independently described
increase in MAO-B expression and activity in brain and platelets
of AD patients (Adolfsson et al., 1980; Bongioanni et al., 1997;
Mészáros et al., 1998). The molecular causes of this change are
currently unknown.
Platelets are preactivated in AD patients
More than ten years ago, Sevush et al analyzed platelet
activation in 91 patients with probable AD and 40 age-matched
control subjects. Groups were compared for percentage of
circulating platelet aggregates, surface expression of P-selectin
(α granule marker), formation of leukocyte-platelet complexes,
and presence of circulating platelet microparticles. The results
showed a significant increase in platelet aggregates, leukocyte-
platelet complexes and P-selectin expression in resting platelets
of AD patients demonstrating that platelets of patients with
AD exhibit greater basal activation than those of controls
(Sevush et al., 1998). More recently, Stellos et al. demonstrated
that integrin αIIbβ3 is activated and P-selectin is expressed on
plasma membrane in unstimulated platelets from AD subjects
compared to control (Stellos et al., 2010; Laske, 2012). More
interestingly, in one-year follow up study platelet activation
parameters correlate with the rate of cognitive decline and anti-
platelet therapy reduced cognitive decline in AD patients (Laske
et al., 2010; Sakurai et al., 2013). As we previously reported,
activated platelets have been shown to adhere to cerebral vascular
deposits of Aβ in AD transgenic mice models, which are known to
develop CAA upon aging. Sustain platelet recruitment to vascular
amyloid plaques results in occlusion of the vessels (Gowert et al.,
2014). The same authors also demonstrated that platelets are
able to process soluble synthetic Aβ into fibrillar Aβ increasing
its neurotoxicity in culture, which suggests an active role of
platelets in promoting neuronal death in AD. Platelet localization
at the site of cerebrovascular injury and in CAA lesions has
been observed in several other studies, which demonstrated
localization of activated platelets with deposit of Aβ peptides
(Roher et al., 2009). This is likely to play an important role in
the establishment of a vicious circle of platelet activation, Aβ
release and neuronal cell death. Once activated, platelets can
release Aβ40 in the circulation, increasing its local concentration
and contributing to accumulation of amyloid peptides in the
vessel of the cerebrovasculature. Amyloid accumulation also
induces microvascular inflammation (Grammas and Ovase,
2001). Platelet deposition in the cerebral microvasculature may
account for the hemostatic abnormalities observed in AD
(Wilkerson and Sane, 2002).
Higher levels of “coated” platelets
Another important parameter of platelet activation is the presence
of increased levels of coated platelets in AD patients. Coated
platelets are a subset of activated platelets observed upon dual-
agonist stimulation with collagen and thrombin characterized
by high pro-coagulant activity (Dale, 2005). Prodan et al.
demonstrated that coated platelets expressed high levels of
full-length APP on their surface compared to single agonist-
stimulated platelets (Prodan et al., 2006). Coated platelets
are increased in early stages of AD, are elevated in patients
with amnestic as compared to nonamnestic MCI, and their
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numbers correlate with disease progression in AD (Prodan
et al., 2007, 2008). Coated platelets are also altered in patients
with cerebrovascular disease and have been show to potentiate
inflammation. These data suggest a role of coated platelets as a
sensitive biomarker of AD (Prodan et al., 2009).
Coagulation abnormalities in AD
Besides platelet hyper activation, coagulation is also impaired in
AD patients. In particular it has been observed that Aβ is able
to bind fibrinogen and that fibrin clot formed in the presence
of Aβ are more stable and more resistant to degradation during
fibrinolysis (Ahn et al., 2010; Cortes-Canteli et al., 2010). After
BBB alterations fibrinogen may deposit to brain blood vessel and
accumulate in CAA and parenchyma in AD patients, and in AD
mouse models (Paul et al., 2007). This could finally results in
altered cerebral blood flow and worsening of the pro-thrombotic
phenotype in cerebral microvasculature of AD patients.
CONCLUSIONS AND FUTURE DIRECTIONS
AD is associated with platelet and vascular abnormalities. Our
understanding of the mechanisms underlying thrombosis and
angiopathy associated with AD is growing exponentially. Several
molecular mechanisms that explain microvascular alterations
associated with AD have been undercovered. Although the role
of tau protein in neuronal death and cognitive ability loss is also
central in AD development, the accumulation of amyloid peptides
is closely related to the vascular abnormalities associated with this
disease. Therefore, this was the subject of this literature review.
Future challenges in this field will be to understand fully the
relevance of the microvascular symptoms of AD in dementia
development and to target them in order to improve the
management of this debilitating disease. This will require a
truly multidisciplinary effort with basic scientists and clinicians
from different areas of research (i.e., neuroscience, cardiovascular
sciences and cell biology) collaborating towards the clarification
of the complex etiology of AD. Biomedical research into the
vascular aspects of AD provides new hopes for early disease
diagnosis and the development of novel clinical strategies to
reduce the rate of cognitive function loss following diagnosis.
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